Introduction
============

One of the common complications of allogeneic hematopoietic stem cell transplantation (HSCT) in children is the occurrence of hemorrhagic cystitis (HC). HC occurring within 48 h after infusion of cyclophosphamide (CY) as a part of conditioning regimen is referred to as early onset and after 48 h as late onset HC ([@B30]). HC incidence in an allogeneic HSCT was reported to be as high as 20% in pediatric patients ([@B13]; [@B16]; [@B23]). A myeloablative conditioning regimen with busulfan (BU) and CY in children undergoing HSCT is often associated with higher incidences of HC compared to the reduced intensity regimen excluding CY ([@B32]; [@B33]). Besides the presence of CY as a component of conditioning, several other risk factors were defined for HC incidence such as viral infections (human BK/JC polyoma virus, Adenovirus, and Cytomegalovirus), unrelated or haploidentical related donor, cord blood transplantation and high doses of BU ([@B36]). Indeed HC is one of the causes of morbidity especially during the pre-engraftment period usually before day 30 post HSCT impacting the overall survival (OS) in pediatric HSCT with 40% OS observed in patients with HC compared to 65% in those without HC ([@B11]). The incidence of HC can be very high (up to 60%) when CY is administered post HSCT as a prophylaxis for GvHD in haploidentical transplant recipients ([@B29]), pinpointing the need for identification of high risk patients prior to CY therapy.

The pathophysiology of HC occurring 24--72 h after HSCT is multifactorial ([@B22]), involving initial chemical injury (damage to the bladder transitional epithelium and the endothelium of blood vessels by BU, CY and their metabolites), viral infections with viruria, immunosuppression, poor immune reconstitution, engraftment process, and HC pathogenesis (**Figure [1](#F1){ref-type="fig"}**). It is well-established that damage to the urothelium is the initial step during pathogenesis of HC. Though it is known that acrolein (Ac, metabolite of CY) contributes to HC development ([@B12]), the role of Sulfolane (Su, water soluble metabolite of BU) is not yet known. It remains unclear whether Su affects the activity of enzymes implicated in CY metabolism (CYP2C9, CYP2C19, and CYP2B6) or if it is directly involved in HC pathogenesis. It was hypothesized that BU metabolites may affect the activity of CYPs, thus influencing the outcomes such as increased occurrence of treatment related toxicity with BU-CY compared to CY-BU administration *via* increased exposure to CY metabolites ([@B10]; [@B28]). However, experimental data on the effect of BU metabolites on CYP function is limited. Moreover, the concentration and time dependent effects of Ac on the urothelium are unknown. With the availability of an analytical method for quantifying Su levels in plasma ([@B39]), it is now possible to investigate its relation to HC incidence in a clinical setting. Several enzymes contribute to the metabolism of Su and CY, for example, CYP2C9 is involved in both the processes of activation of CY and formation of Su from BU ([@B38]). Flavin monooxygenase (FMO3) is involved in Su formation, while CYP2B6, CYP2C19, alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH3A1) are involved in either activation or inactivation of CY ([@B35]; [@B40]). The metabolic pathway of CY is outlined in Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}.

![Hypothetical model for Hemorrhagic Cystitis occurrence in children receiving BU-CY regimen prior to allogeneic HSCT. Busulfan (BU) and cyclophosphamide (CY) metabolism predominantly occurs in the liver generating the water soluble metabolites sulfolane (Su) and acrolein (Ac), respectively. During the metabolic process BU utilizes glutathione (GSH) and activity of GSTs such as GST alpha 1 (GSTA1), GST mu1 (GSTM1) plays an important role in conjugation of BU with GSH. GSH is also essential for scavenging the CY active metabolites including Ac also catalyzed by GSTs. When CY is administered after BU, the water soluble metabolite of BU, i.e., Su could influence the activity of cytochrome P 450 enzymes (CYPs) and thus might affect the activation of CY, or on the other hand higher Su levels also represents the utilization of GSH and formation of γ-glutamyl-dehydroalanyl-glycine (EdAG) affecting the availability of reduced form of GSH. Su might also affect the function of GSTs and other enzymes in BU, CY metabolism and proteins such as Mitochondrial uncoupling proteins (UCP) encoded by SLC25A27 gene affecting cell survival. Su possibly affect the function of ADH (alcohol dehydrogenase) enzyme resulting in increased levels of hydroxy CY metabolite, resulting increased Ac formation. BU could irreversibly alkylate the glutaredoxins (Grx) and Thioredoxins (Trx) increasing the oxidative stress, thus increasing toxicity of incoming CY metabolites such as 4 hydroxy cyclophosphamide (4OH-CY); Ac, chloro acetaldehyde (CA), and Phosphoramide mustard (PM). Altered activity of CYPs due to less functional alleles in the encoding genes might have a predictable function of Su formation and CY activation. Circulating CY metabolites (4OH CY, PM) including Ac inhibit cytokine function by alkylation and also cause immunosuppression, further increasing the chances of viremia and viruria (BK and/or JC virus). Ac conjugated with GSH in the liver gets delivered to the bladder and releases free Ac which then could alkylates cysteine residues and causing toxicity. Altogether increased rate of metabolite delivery to the urinary bladder together with viral load and lack of protection due to increased oxidative stress, endothelial damage to the blood vessels, urothelial damage and enhanced viral replication results in bladder inflammation and hematuria and the condition hemorrhagic cystitis.](fphar-08-00451-g001){#F1}

The participation of several glutathione *S* transferase (GST) isoforms in eliminating BU and CY intermediate metabolites also indicates their importance in the etiology of HC, especially isoforms that are predominantly expressed in all tissues including urothelium, such as *GSTM1*. Moreover, variations in these genes may affect enzyme activity that in turn affect CY and BU metabolism contributing to the development of HC. In this retrospective study, the role of Su levels, selected genetic variants in CY metabolism genes, and Su formation were investigated with relation to the incidences of HC. Functional studies with human urothelial cells (HUCs), and human hepatic/hepatoma cells (HepaRG/HepG2) as well as with alcohol dehydrogenase enzyme (ADH) were also conducted to explore the cytotoxic potential of Su, Ac and ADH enzyme modulating effects of Su.

Materials and Methods {#s1}
=====================

Study Subjects
--------------

This retrospective analysis was conducted in 72 children recruited from St. Justine Hospital (CHUSJ), Montreal, Canada and University Hospital of Geneva (HUG), Geneva, Switzerland between 2001 and 2013. Su levels were measured in 39 patients due to non-availability of plasma from the rest. Local Institutional Ethics Committee at each center approved the study and all patients or their parents signed the informed consent. Details of inclusion criteria are available at Clinicaltrials.gov site (NCT01257854).

Conditioning Regimen, Measurement of Plasma Levels of Sulfolane, and Hemorrhagic Cystitis Diagnosis Criteria
------------------------------------------------------------------------------------------------------------

All patients received i.v. BU (Days -9 to -6 of HSCT) followed by i.v. CY (days -5 to -2 of HSCT). BU was administered by i.v. route in 16 doses as a 2 h infusion every 6 h. BU first dose pharmacokinetic parameters were estimated and adjusted from the 3rd to 6th dose, aiming to achieve a steady state concentration between 600 and 900 ng/mL ([@B4]). I.V. CY was administered as a 2 h infusion at 50 mg/kg/day and each patient received a cumulative dose of 200 mg/kg. 2-mercaptoethane sulfonate (MESNA; UROMITEXAN^®^) was administered as a 15 min i.v. infusion at 25 mg/kg/dose, one dose 15 min prior to CY and three doses at 3, 7, and 11 h from the beginning of CY therapy. Patients were hyper hydrated with 3000 mL/m^2^/day during and until 24 h after the end of CY administration. Plasma from patients collected before dose 7 and after dose 9 BU infusions were used for measuring Su levels using gas-chromatography and mass spectrometry ([@B39]). Plasma levels of Su were normalized with cumulative BU dose in mg/kg (up to dose 6 for before dose 7 Su levels, up to dose 9 for after dose 9 Su levels).

Hemorrhagic cystitis was defined as the presence of hematuria (both microscopic and macroscopic) from the initiation of the conditioning regimen up to 30 days post-transplant, which is usually considered as engraftment period (0--30 days). HC was graded according to the criteria described previously ([@B17]): grade I = microscopic hematuria, grade II = macroscopic hematuria, grade III = macroscopic hematuria with clots, and grade IV = macroscopic hematuria with clot needing instrumentation for clot evacuation or leading to urinary retention or requiring surgical intervention.

Genotyping and Gene Expression Analysis
---------------------------------------

Genomic DNA extracted from peripheral mononuclear cells of patients before they received the conditioning regimen was used for genotyping relevant genetic variants. The list of chosen genetic variants, functionality and the genotyping method used are enlisted in **Table [1](#T1){ref-type="table"}**. RNA was extracted from HepaRG cells using PureLink^®^ RNA mini kit (Thermo Fischer Scientific), was converted to cDNA using SuperScript^®^ VILO^TM^ cDNA Synthesis Kit (Thermo Fischer Scientific) and was used for gene expression experiments with gene specific primers (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}) using SYBR^®^ Green Real-Time PCR Master Mix (Thermo Fischer Scientific). The primers were tested for efficiency at five different levels, and *GAPDH* was used as the internal control gene. TaqMan genotyping and gene expression assays (in triplicates on three different occasions) were performed on StepOnePlus real time PCR system (Thermo Fischer Scientific).

###### 

The list of genetic variants genotyped in the selected genes and the minor allele frequencies observed in the study population.

  SNP (rsID)                  Nucleotide variation (amino acid change) functional impact in homozygous carriers                                Method                                Real time PCR assay ID        Minor allele frequency (*n* = 144)   Heterozygosity (*n* = 72)
  --------------------------- ---------------------------------------------------------------------------------------------------------------- ------------------------------------- ----------------------------- ------------------------------------ ---------------------------
  GSTM1^∗^0                   Deletion No enzyme activity                                                                                      PCR/melt curve SYBR green chemistry   See main text for reference   48.6                                 \_\_\_\_
  CYP2C9^∗^2 (rs1799853)      c.430C \> T (p.Arg144Cys) Decreased activity                                                                     Real time DME Taqman assay            C_25625805_10                 12.5                                 16.7
  CYP2C9^∗^3 (rs1057910)      c.1075A \> C (p. Ile359Leu) Decreased activity                                                                   DME Taqman assay                      C_27104892_10                 8.3                                  16.7
  CYP2C19^∗^2 (rs4244285)     c.681G \> A in exon 5 Splicing defect and no enzyme activity                                                     DME Taqman assay                      C_25986767_70                 12.5                                 22.2
  CYP2C19^∗^17 (rs12248560)   c.-806C \> T and c.-3402C \> T (promoter region polymorphism) Increased expression of CYP2C19 and its activity   DME Taqman assay                      C_469857_10                   19.4                                 27.8
  FMO3^∗^ (rs2266780)         Glu308Gly; missense variation                                                                                    DME Taqman assay                      C\_\_2220257_30               20.8                                 27.8
  FMO3^∗^ (rs2266782)         Glu158Lys; missense variation                                                                                    DME Taqman assay                      C\_\_2461179_30               43.1                                 38.9
  FMO3^∗^ (rs1736557)         Val257Met; missense variation                                                                                    DME Taqman assay                      C\_\_8698544_30               7.6                                  15.3
  CYP2B6^∗^5 (rs3211371)      Arg487Cys; decreased enzyme activity                                                                             DME Taqman assay                      C_30634242_40                 13.9                                 22.2
  CYP2B6^∗^9 (rs3745274)      Gln172His; decreased enzyme activity                                                                             DME Taqman assay                      C_7817765_60                  28.5                                 29.2
  ALDH3A1^∗^2 (rs2228100)     Pro329Ala; decreased activity                                                                                    Taqman assay                          C\_\_\_7443700_60             34.0                                 34.7
  SLC25A27 (rs9381468)        c.299-346A \> G; influence on function or expression not known                                                   Taqman assay                          C\_\_29893451_10              45.1                                 51.4
  SLC25A27 (rs953062)         c.299-346A \> G; influence on function or expression not known                                                   Taqman assay                          C\_\_11541519_20              37.5                                 45.8

∗

Single-nucleotide polymorphisms (SNPs) in FMO3 gene were predicted to be tolerant using prediction tools such as sorting intolerant from tolerant (SIFT) and protein analysis through evolutionary relationships (PANTHER), except rs2266780 that was predicted to be damaging to gene function by SIFT

.

Human Urothelial (HUC), Hepatoma (HepG2), and Hepatic (HepaRG) Cell Culture
---------------------------------------------------------------------------

Human urothelial cells (ScienCell Research laboratories) were obtained from Chemie Brunschwig, Basel and were cultured in urothelial cell medium (ScienCell Research laboratories) supplemented with growth factors as per the instructions by the supplier (ScienCell) on poly-[L]{.smallcaps}-lysine-coated (0.01% from Sigma--Aldrich) culture vessels (BD Biosciences) at 37°C and 5% CO~2~. HUC Cells were seeded at a density of 5000 cells/cm^2^ and were passaged when reached 80--90% confluence using trypsin EDTA (Lifescience technologies), and all experiments were performed in between passages 2 and 6.

Undifferentiated hepatic cells (HepaRG) were procured from Biopredic^®^ (Saint-Gregoire, France) and were cultured based on the protocol by [@B5] for stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Undifferentiated HepaRG cells (passage 18) were seeded on day 1 in 75 cm^2^ flasks at a density of 2.6 × 10^4^ cells/cm^2^ in a culture medium composed of Williams medium E, supplemented with 10% fetal bovine serum (FBS), 2 mM Glutamax^TM^, 50 μM hydrocortisone hemisuccinate, 5 μg/mL insulin, 100 IU/mL penicillin, and 100 μg/mL streptomycin at 37°C and 5% CO~2~. Culture medium was changed every 2--3 days. On day 15, cells were confluent and differentiation was induced by adding 1.5% DMSO in the culture medium (differentiation medium). On day 29, differentiated HepaRG cells were detached by gentle trypsinization and plated in 24-wells at a density of 2 × 10^5^ cells/cm^2^ in the same differentiation medium.

HepG2 cell lines (ATCC) were cultured using DMEM medium (Life technologies) supplemented with 10% FBS (AMMED), at 37°C and 5% CO~2.~ Experiments were performed at passage numbers 80--95.

Evaluation of CYP Function and Expression in HepaRG Cells
---------------------------------------------------------

HepaRG cells preincubated with Su were used for CYP phenotyping and expression analysis. On day 36, differentiation medium was replaced by the induction medium (culture medium deprived of DMSO and FBS). On days 37, 38, and 39 Su was added to the induction medium at concentrations ranging from 0.5 to 5 μM. Rifampicin (10 and 50 μM) and phenobarbital (500 and 1000 μM) were used as positive controls. Final concentration of DMSO during the time of induction was 0.1%. On day 40 after 72 h of induction, cells were washed three times with phenol-red free Williams medium E and a probe cocktail composed of midazolam 5 μM (CYP3A4), *S*-mephenytoin 50 μM (CYP2C19), bupropion 50 μM (CYP2B6), flurbiprofen 10 μM (CYP2C9), and phenacetin 10 μM (CYP1A2) in phenol-red free Williams medium E was incubated for 3 h. The incubation medium was removed and stored at -80°C for further quantification of the metabolites released in the medium. All the cells from triplicate wells were detached by gentle trypsinization (100 μL of trypsin-EDTA 0.05% per well), homogenized by pipetting cell suspension up and down and samples were split into two parts. Cells were then washed twice with phosphate buffer saline. The first half of the cells was lysed with RIPA buffer (Thermo Scientific) for further protein quantification using bicinchoninic acid assay. The other half of cells was used for RNA extraction and cDNA synthesis followed by gene expression analysis. The experiment was repeated twice on different occasions with each exposure in triplicate wells. Though CYP1A2 probe was included in the cocktail, only the results of CYP2C9, CYP2C19, CYP2B6, and CYP3A4 probes are presented in this report.

For phenotyping, incubation medium samples were thawed at room temperature and extracted with ethyl acetate 2:1 (v:v). Hydroxymidazolam-d4, paracetamol-d3, hydroxymephenytoin-d3 and hydroxybupropion-d6 were added as internal standards (33 ng/ml). The organic phase was transferred to a clean tube, evaporated with a vacuum concentrator Mivac^®^ (Genevac, Ipswich, United Kingdom) and then reconstituted with water/acetonitrile (80:20). Metabolites were quantified by high-performance liquid chromatography (HPLC) tandem mass spectrometry (MS). Chromatography was performed in a gradient mode with an Agilent series 1100 (Waldbronn, Germany) LC system composed of a Discovery C18 column (5 μM particle size, 15 cm × 2.1 mm) preceded by a Discovery pre-column (5 μM; 5 cm × 2.1 mm; Supelco^®^, Bellefonte, PA, United States) at 20°C. The HPLC eluents were water + 0.1% formic acid (mobile phase A) and acetonitrile + 0.1% formic acid (mobile phase B).

The tandem mass spectrometry experiments were performed with an API 4000 triple quadrupole mass spectrometer (AB Sciex, Concord, ON, Canada) controlled by Analyst 1.5.1 Software. The mass spectrometer was operated in the multiple reaction monitoring (MRM) mode with both positive and negative electrospray ionizations. Chromatographic conditions following sample injection (10 μl) were as follows: initial conditions were 2% mobile phase B, and then mobile phase B was increased by gradient up to 90% from 0.1 to 3 min. This condition was kept during 1 min and then initial conditions were applied until the end of the run. Mobile phase flow rate was maintained at 0.35 mL/min and chromatography performed at 20°C with the total run time per injection of 10 min for positive mode and 9 min for negative mode. Transitions of the probe drug metabolites quantified by mass spectrometry are described in Supplementary Table [S2](#SM1){ref-type="supplementary-material"}.

Evaluation of Alcohol Dehydrogenase (ADH) Inhibition by Sulfolane
-----------------------------------------------------------------

Alcohol dehydrogenase inhibition assays were performed as previously described ([@B19]) with few modifications. In brief, ADH inhibition was assessed using ethanol at 10 mM concentration as a substrate for ADH (Sigma--Aldrich). The enzyme activity catalyzed by ADH was measured by monitoring NADH. The enzyme reaction was started by mixing ethanol, NAD+ and ADH in a buffer. Tecan sunrise spectrophotometer (Tecan) was used to measure the accumulation of NAD+ by measuring absorbance of light at 340 nm. The rate of the reaction was reported as change in the absorbance of light (340 nm) per minute (ΔA340/min). Initially with NAD+ at 1.5 mM and ADH concentration of 0.005 unit/0.2 mL, we observed 8--13 mM as a Michaelis--Menten constant (Km) of ADH with ethanol as substrate. This reaction was linear within a 30-min time range. Further inhibition experiments were conducted using same conditions to measure ADH activity with pre-incubations of pyrazole (known inhibitor of ADH) at 1, 5, 10, 50, 100, 500, and 1000 μM and Su at 0.1, 0.5, 1, 5, 10, 50, and 100 μM concentrations.

IC50 Screening, Cell Viability, and AnnexinV Assays Following Incubation with Ac or Su
--------------------------------------------------------------------------------------

IC50 screening and apoptotic behavior of cells by annexin assay was performed with a series of Ac and Su concentrations. For IC50 screening in HUC cells, 4000 cells were seeded in a poly [L]{.smallcaps}- lysine (0.01%) coated 96 well plate followed by incubation with a series of concentrations of either Ac (0.084, 0.84, 4.2, 8.4, 84, 168, 336, and 672 μM) or Su (0.01, 0.1, 1, 10, 100 mM) for about 48 h followed by WST-1 assay (Roche). IC50 values were determined by non-linear curve fitting of absorbance readings at 450 nm against the concentrations. Since both Ac, and Su are water soluble agents, they were easily dissolved in the culture medium to obtain appropriate concentrations. Further, these observations were confirmed by trypan blue exclusion method and microscopical examination of cells.

For AnnexinV binding assays, 125,000 cells were seeded in a 25 cm^2^ flask coated with 0.01% poly-[L]{.smallcaps}-lysine. Cells were incubated for 24 h, followed by exposure to either Ac (33, 50, 84, 250, 500, and 830 μM) or Su (0.1 and 1 mM) for 30 and 60 min. After treatment, cells were incubated in fresh medium for 48 h and were harvested by trypsinization (0.05%). Fractions of live, early apoptotic, late apoptotic, and dead cells were measured using Fluorescein isothiocyanate (FITC) Annexin V Apoptosis Detection Kit I (BD pharmingen, BD biosciences) according to manufacturer's instructions. Flow cytometric analysis was carried out using CyAn ADP (Beckman Coulter) flow cytometer. FITC Annexin V was measured at FL1 (excitation laser: 488 nm; emission filter: 530/40), PI was measured at FL6 (excitation laser: 561 nm, emission filter: 586/15), no compensation was necessary. A minimum of 4000 cells per sample were analyzed. Gates were adjusted based on the same batch of HUC cells which were unlabeled and labeled either by FITC Annexin V or propidium iodide only. Results are given as fraction of live, early apoptotic, late apoptotic and dead cells in the whole cell population.

Statistical Analysis
--------------------

Statistical analyses were performed using IBM^®^ SPSS^®^ statistics (version 22, SPSS, Inc., Armonk, NY, United States). Two sided *p*-values were represented and a probability of less than 0.05 was considered as statistically significant. Mann--Whitney *U*-test was used to analyze the differences in demographics between groups of with and without HC. A receiver--operator characteristic curve (ROC) for Su levels, age and weight was plotted to show the trade-off in sensitivity vs. 1- specificity rates for HC, as the cut-off of the test was shifted from low to high. Mann--Whitney *U*-test was used to analyze the relation of Su levels and HC. Cumulative incidences of HC were estimated using Kaplan--Meier curves and log-rank test was used to compare the difference between groups divided based on cutoff defined in ROC curves, in univariate analysis. In univariate analysis the variables included were: age (age above and below 10 years), weight (above and below 30 kg), *CYP2C9* and *GSTM1* combined genotypes (normal vs. variant), *FMO3* (normal vs. variant), other genotypes (Normal vs. variant), source (cord blood vs. bone marrow), aGvHD prophylaxis (Cyclosporine vs. Cyclosporine + steroid vs. cyclosporine+ methotrexate) diagnosis (malignant vs. non-malignant), donor type (matched related, matched unrelated, mismatched related, and mismatched unrelated) and serotherapy (received vs. not received). Multivariate analysis was performed including significant co-variates in univariate analysis using Cox (Proportional Hazards) regression to estimate hazard ratios (HR) with 95% confidence intervals (CIs). As there is a correlation between age and weight, in the multivariate analysis, we used only age as a co-variate. Multivariate analysis with Su levels was performed including either dose 7 or dose 9 levels together with age. Competing risk-analysis was not performed as the competing events such as non-relapse mortality and relapse occurred only after HC occurrence (only one patient) or not occurred before day 30 post-transplant. IC50 values for Ac and Su were calculated using non-linear regression using GraphPad Prism version 6.0 for Windows (GraphPad Software, La Jolla, CA, United States^[1](#fn01){ref-type="fn"}^) with a correlation coefficient set to a minimum of 0.85 and including at least 20 points for curve fitting. The CYP activity phenotyping results are presented as a fold change compared to that of control group.

Results
=======

The demographic and clinical characteristics of patients with and without HC are outlined in **Table [2](#T2){ref-type="table"}**. The overall demographic and transplant characteristics are summarized in Supplementary Table [S3](#SM1){ref-type="supplementary-material"} and clinical outcomes other than HC are summarized in **Table [3](#T3){ref-type="table"}**. Cumulative incidence of HC was observed to be 15.3%, median time to occurrence of HC was 23 days and to resolve HC was 32 days post HSCT. BK or JC viruria was detected in 9 patients tested out of 11 with HC and thus the cause could be attributed mainly to their presence. As for the remaining, etiology of HC was unknown. Seven out of eleven patients with HC (63.6%) engrafted before the occurrence of HC. Please refer to **Table [4](#T4){ref-type="table"}** for clinical characteristics of patients with HC.

###### 

Demographic and transplant characteristics of the patients included in the study.

                                              39 Children with Su levels   Total 72 Children                                        
  ------------------------------------------- ---------------------------- ------------------- ------------------ ----------------- -------------------
  Gender                                      Male                         4 (21.1)            15 (78.9)          6 (16.7)          30 (83.3)
                                              Female                       4 (20.0)            16 (80.0)          5 (13.8)          31 (86.2)
  Diagnosis                                   Malignant disease            6 (26.1)            17 (73.9)          9 (20.5)          35 (79.5)
                                              Non-malignancy               2 (12.5)            14 (87.5)          2 (7.1)           26 (92.9)
  Source                                      Bone marrow                  2 (11.1)            16 (88.9)          3 (9.7)           28 (90.3)
                                              Cord blood                   6 (28.5)            15 (71.5)          8 (19.5)          33 (80.5)
  HLA match                                   MRD                          1 (7.1)             13 (92.9)          2 (7.4)           25 (92.6)
                                              MMRD                         0                   3 (100)            0                 3 (100)
                                              MUD                          1 (16.6)            5 (83.4)           1 (7.7)           12 (92.3)
                                              MMUD                         6 (37.5)            10 (62.5)          8 (27.6)          21 (72.4)
  Serotherapy                                 ATG (yes/no)                 6/2 (75/25)         24/7 (77.4/22.6)   8/3 (72.7/27.3)   47/14 (77.1/22.9)
  GvHD prophylaxis                            Cyclosporine                 0                   1 (100)            0                 2 (100)
                                              Cyclosporine+steroids        5 (25.0)            15 (75.0)          7 (18.4)          31 (81.6)
                                              Cyclosporine+ methotrexate   3 (16.7)            15 (83.3)          4 (12.5)          28 (87.5)
                                                                                                                                    
  **Characteristic**                          **Median (mean)**                                                                     
                                                                                                                                    
  Age (years)                                 14.5 (12.6)                  5.6 (6.2)           12.7 (15.0)        5.6 (6.8)         
  Weight (kg)                                 45.4 (44.9)                  21.5 (23.8)         49.2 (45.3)        21.5 (25.8)       
  BU cumulative dose in mg/kg                 14.5 (14.7)                  16.1 (16.2)         13.9 (14.8)        15.9 (16.0)       
  CY cumulative dose in mg/kg                 200                          200                 200                200               
  Su levels before dose 7 (ng/mL//mg/kg)^1^   50.7 (48.3)                  34.4 (35.1)         NA                 NA                
  Su levels after dose 9 (ng/mL//mg/kg)^2^    40.7 (40.5)                  29.9 (30.9)         NA                 NA                

∗

Six of them were positive for BK virus and one patient for JC virus in urine. Age, weight, Su (sulfolane) levels differed significantly between the two groups (

p

\< 0.05). All of them received MESNA as prophylaxis.

¥

Eight of them were positive for BK virus and one for JC virus in urine.

1,2

Sulfolane levels were normalized with the BU dose received till that level in mg/kg. HC, hemorrhagic cystitis; MRD, matched related donor; MMRD, mismatched related donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor

.

###### 

Cumulative incidences of clinical outcomes other than hemorrhagic cystitis.

  Clinical outcomes                            Cumulative incidence   Day of onset           
  -------------------------------------------- ---------------------- -------------- ------- ----------
  Neutrophil recovery(Day 100)                 64                     88.8           18      10--48
  Platelet recovery (Day 180)                  59                     81.9           42      16--173
  Sinusoidal obstruction syndrome (SOS)        7                      9.7            11      4--26
  Acute graft vs. host disease (grades 2--4)   9                      12.5           95      30--162
  Death                                        14                     19.4           183.5   28--1259
  Relapse^∗^                                   11                     25.0           163     44--384
  Rejection                                    7                      9.7            45      33--246

∗

Frequencies are calculated for malignancies alone

.

###### 

Clinical characteristics of patients with hemorrhagic cystitis.

  Patient no   Age (Y)   Weight (Kg)   Sex   Diagnosis           Donor source   Etiology of HC   *CYP2C9* diplotype   *GSTM1* genotype   HC grade   Day of onset of HC   Day when HC was resolved^∗^   Day of neutrophil engraftment^∗^
  ------------ --------- ------------- ----- ------------------- -------------- ---------------- -------------------- ------------------ ---------- -------------------- ----------------------------- ----------------------------------
  HC1          6.5       25.0          M     MDS                 CB             BK               ^∗^1^∗^1             NonNull            3          25                   39                            15
  HC2          16.8      52.8          M     MPD                 BM             BK               ^∗^1^∗^1             NonNull            1          28                   40                            31
  HC3          3.1       14.3          F     AML                 CB             BK               ^∗^1^∗^2             NonNull            2          23                   32                            18
  HC4          16.8      65.3          M     AML                 CB             BK               ^∗^1^∗^1             NonNull            2          24                   129                           19
  HC5          5.2       24.1          M     AML                 CB             BK               ^∗^1^∗^1             NonNull            3          23                   38                            14
  HC6          17.1      49.2          F     AML                 BM             unknown          ^∗^1^∗^1             NonNull            2          3                    7                             18
  HC7          13.9      56.1          M     MDS                 CB             JC               ^∗^1^∗^1             Null               2          3                    9                             No engraftment
  HC8          19.9      77.5          F     Immunodefficiency   CB             BK               ^∗^1^∗^1             NonNull            3          27                   47                            34
  HC9          15.0      64.2          F     AML                 CB             unknown          ^∗^1^∗^1             NonNull            1          18                   22                            43
  HC10         15.1      38.0          M     Immunodefficiency   BM             BK               ^∗^1^∗^1             NonNull            3          20                   30                            16
  HC11         10.2      31.3          F     ALL                 CB             BK               ^∗^1^∗^1             Null               2          11                   13                            14

∗

Days post-hematopoietic stem cell transplantation. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; F, female; BK virus, human polyoma virus named after the patient initials in which it was isolated first. CB, cord blood; BM, bone marrow; HC, hemorrhagic cystitis; JC virus, John Cunningham human polyoma virus. M, male; MDS, myelodysplastic syndrome; MPD, myelo proliferative disorder; Virus were detected in urine (viruria); grade I = microscopic hematuria; grade II = macroscopic hematuria; grade III = macroscopic hematuria with clots, and grade IV = macroscopic hematuria with clot needing instrumentation for clot evacuation or leading to urinary retention or requiring surgical intervention

.

Sulfolane Levels, Age, and HC
-----------------------------

We observed higher Su levels (ng/mL//mg/kg) before dose 7 (mean ± SD; 48.3 ± 11.2 vs. 35.1 ± 15.3; *p* = 0.02) and after dose 9 (40.5 ± 9.6 vs. 30.9 ± 14.4; *p* = 0.03) in patients with HC (*n* = 8) compared to those without HC (*n* = 31, **Figures [2A,B](#F2){ref-type="fig"}**), respectively. Cutoff values of 49.44 and 36.28 were chosen in ROC analysis for Su levels before dose 7 and after dose 9, respectively, with better sensitivity and specificity for HC occurrence (**Figure [2C](#F2){ref-type="fig"}**). Patients with Su levels above the cutoff value (before dose 7, 41.7%; after dose 9, 42.9%) had higher incidence of HC compared to those below the cutoff (before dose 7, 11.0%; after dose 9, 8.0%) at both dose levels (**Figures [2D,E](#F2){ref-type="fig"}**). Age and weight were also correlated with the incidence of HC, with higher incidence in patients older than 10 years, and weighed above 30 kg (defined by ROC curves, Supplementary Figures [S2A--C](#SM1){ref-type="supplementary-material"}). Higher levels of Su correlated with the weight and age of the patients. In multivariate analysis with Su levels and age, Su levels before dose 7 (HR: 4.6; 1.1--19.4; *p* = 0.03) and after dose 9 (HR: 6.6; 1.3--32.8; *p* = 0.02) were independently associated with HC.

![Sufolane levels and occurrence of Hemorrhagic cystitis. **(A,B)** Su levels between patients with and without HC. **(C)** ROC curve for Su levels as a predictive marker for HC (*n* = 39). A cut off of 49.43 and 36.28 ng/mL/mg/kg for HC, before dose 7 and after dose 9, respectively \[before dose 7; Area = 0.75 (95% CI: 0.59--0.93; *p* = 0.02); after dose 9; Area = 0.74 (95% CI: 0.57--0.91), *p* = 0.03\]. **(D,E)** Cumulative incidences HC. Patients with HC/total number of patients in each group. **(D)** Before dose 7 **(E)** after dose 9.](fphar-08-00451-g002){#F2}

CYP2C9, GSTM1 Genotypes and HC Occurrence
-----------------------------------------

The minor allele and heterozygosity frequencies of the genetic variants studied are given in **Table [1](#T1){ref-type="table"}**. Higher incidences of HC were observed in *CYP2C9 ^∗^1^∗^1* (22.2%), *GSTM1* nonNULL genotype carriers (24.3%) and in patients carrying both functional *GSTM1* and *CYP2C9* genotypes (33.3%) compared to those carrying non-functional allele in either one of the genes (6.3%; **Figures [3A](#F3){ref-type="fig"}--[C](#F3){ref-type="fig"}**). No significant associations between HC and other SNPs investigated were noted. In multivariate analysis including age, combined *GSTM1* and *CYP* genotype status was independently associated with HC with an HR of 4.8 (95% CI: 1.3--18.4; *p* = 0.02; **Figure [3C](#F3){ref-type="fig"}**). Su levels differed significantly between children who are above and below 10 years of age (Supplementary Figures [S3A,B](#SM1){ref-type="supplementary-material"}). We observed a trend of higher Su levels in children carrying both normal *CYP2C9* and *GSTM1* genotypes compared to those carrying either one or both dysfunctional genotypes (Supplementary Figures [S3C,D](#SM1){ref-type="supplementary-material"}). However, Su levels did not differ significantly between these two genotype groups (Supplementary Figures [S3C,D](#SM1){ref-type="supplementary-material"}).

![Incidence of Hemorrhagic cystitis. **(A)** in relation to the *CYP2C9* genotype status. Group I represents patients without dysfunctional alleles, and II represents carriers of at least one dysfunctional allele. **(B)** In relation to *GSTM1* genotype, group I represents nonNull carriers; and group II represents Null allele carriers. **(C)** In relation to combined *CYP2C9* and *GSTM1* genotypes group I represents carriers of normal functional *CYP2C9* and *GSTM1* genotypes and group II represents carriers of at least one dysfunctional allele in either *CYP2C9* or *GSTM1* or both. Number of patients with HC/total number of patients in each group and *p*-values are mentioned on the plots. Multivariate Cox-regression *p*-value and hazards ratio with 95% confidence intervals are mentioned for 3C.](fphar-08-00451-g003){#F3}

Effect of Su and Ac on HUC Cell Viability
-----------------------------------------

Su did not affect the cell viability of HUC cells at concentrations up to 1 mM ( = 120.2 μg/mL; Supplementary Figures [S4A,B](#SM1){ref-type="supplementary-material"}). Ac was found to affect the morphology and viability and attachment of cells at concentrations above 33 μM when incubated for short time (Supplementary Figures [S4A,B](#SM1){ref-type="supplementary-material"}). The IC50 value for Ac in HUC cells was found to be 516 μM = 28.9 μg/mL (*R*^2^ = 0.92; degrees of freedom 21). Incubation of HUC with Ac for 1 h proved to be toxic and cells were apoptotic and morphology represented shrinking, round cells with fragmented nuclei. Cells started detaching from the surface following growth arrest with no live cells seen attached after 48 h. Ac showed higher binding of annexin V and increased apoptosis in HUC cells at 33 μM = 1.8 μg/mL and 50 μM = 2.8 μg/mL (Supplementary Figure [S5A](#SM1){ref-type="supplementary-material"}) and Su did not show any increase in apoptosis at concentrations lower than 1 mM (Supplementary Figure [S5B](#SM1){ref-type="supplementary-material"}).

Su and Ac on HepG2 Cell Lines
-----------------------------

Su was not found to be toxic in HepG2 cell lines at concentrations up to 1 mM (Data not shown). Ac was toxic to HepG2 cell lines at concentrations as low as 84 μM = 4.7 μg/mL and LD50 value for Ac in HepG2 cell lines was found to be 325 μM = 18.2 μg/mL (Data not shown). The cells were shrunk and showed apoptotic changes after incubation with Ac up to 24 h (Data not shown).

Su Effect on CYP Activity and Expression in HepaRG Cells
--------------------------------------------------------

HepaRG exposed to different levels of Su did not show significant differences in CYP activity (Supplementary Figure [S6](#SM1){ref-type="supplementary-material"}). No significant differences were seen at the level of *CYP* gene expression (Supplementary Figure [S7](#SM1){ref-type="supplementary-material"}). Known inducers of CYPs like phenobarbitone and rifampicin exhibited induction unlike Su (Supplementary Figures [S6](#SM1){ref-type="supplementary-material"}, [S7](#SM1){ref-type="supplementary-material"}). Data from these experiments indicates no significant impact of Su on CYP activity and expression in *HepaRG* cells. The only exception was with CYP2B6, where it resulted in a twofold induction, only at the mRNA level (Supplementary Figure [S7](#SM1){ref-type="supplementary-material"}) but it did not exhibit increased activity when phenotyped with the probe drug for CYP2B6.

ADH Inhibition Assays
---------------------

No inhibitory effect of Su on ADH was observed. Where as known inhibitor pyrazole did inhibit ADH activity in the same experiment with an IC50 consistent with previous reports (Supplementary Figure [S8](#SM1){ref-type="supplementary-material"}).

Discussion
==========

The major finding of this study is the clinical association of HC with *CYP2C9* and *GSTM1* genotype status and age. In this study, we established and provided evidence for a concentration dependent toxic effect of Ac in HUC cells. We have also demonstrated that exposure of urothelium to Ac at shorter times is sufficient to cause damage to the urothelium as evidenced by the increased apoptosis in HUCs exposed to Ac for up to 30 min. These observations suggest that circulating unconjugated Ac causes deleterious effects on the endothelium of blood vessels and on capillary plexus in the submucosal layer. Previously it has been demonstrated that Ac is toxic to the pulmonary endothelial cells and bronchial epithelial cells at concentrations ranging from 25 μM = 1.4 μg/mL to 100 μM = 5.6 μg/mL ([@B14]; [@B24]; [@B20]). Ac can readily form adducts with proteins as it is a soft electrophile and participates in Michael adducts formation resulting in cellular apoptosis as an end effect ([@B9]). In this study we did observed lethal effect of Ac to urinary epithelial cells at concentrations as low as 1.8 μg/mL, suggesting that circulating unconjugated Ac might also have contributed to the urinary toxicity in addition to Ac reaching the bladder. Water soluble metabolite of BU, Su was not toxic to HUC cells up to concentration of 1 mM = 120.2 μg/mL which is several fold higher than the measured concentrations in plasma after BU administration ([@B39]).

Based on these observations we hypothesize that Su serves as a marker of increased BU conjugation with glutathione (GSH) and higher CYP2C9 activity and, thus representing a population with increased CY activation. The cumulative BU doses did not differ between the patients with and without HC (**Table [2](#T2){ref-type="table"}**) indicating that the variability could be at the level of Su formation from the parent drug by the CYP2C9 enzyme. We previously demonstrated the role of CYP2C9 in Su formation from BU ([@B38]). In this analysis we did observe a trend of higher Su levels in children carrying both normal *CYP2C9* and *GSTM1* genotypes, but was not statistically significant (Supplementary Figure [S3](#SM1){ref-type="supplementary-material"}). Su did not display any influence on CYP2C9, 19, 3A4, and 2B6 activities at the level of phenotyping or at the level of mRNA expression *in vitro*, supporting the hypothesis that depletion of GSH and BU action on cysteine rich proteins might be the cause for increased toxicity of CY metabolites when CY is given after BU. The formation of Su indicates the simultaneous formation of GSH analog γ-glutamyl-dehydroalanyl -glycine (EdAG) ([@B38]), another metabolite which inhibits GSH irreversibly, and also participates in increased formation of protein adducts of glutaredoxins and thus increasing oxidative stress and cellular apoptosis together with BU ([@B31]). Thus Su levels might reflect these sequential events predisposing to HC.

It is well-known that the metabolite of CY, Ac is urotoxic ([@B21]). Ac and other active metabolites of CY are eliminated by GSH conjugation catalyzed by GSTs ([@B12]). Ac spontaneously reacts with GSH and other thiols, and the formation of such Michael adducts of Ac-GSH is catalyzed by GSTs ([@B8]). Other mechanisms of detoxification such as conjugation with cysteine residues to form mercapturates are also possible ([@B26]). Target specific expression of GSTs determines sensitivity of the tissues to the toxicity of agents specifically eliminated via conjugation with GSH. GSTM1 is expressed in both the liver and urinary bladder ([@B37]), we postulate that increased conjugation of Ac with GSH in children with GSTM1 normal function facilitates its delivery to the bladder ([@B15]; [@B26]) which could directly damage the urinary bladder epithelium upon its release from GSH conjugate, initiating the pathogenesis of HC. However, In support of this hypothesis, we could not measure either plasma or the urinary Ac levels from these children due to the non-availability of samples, and due to the retrospective nature of this study. On the other hand, inhibition of DNA repair process and downregulation of nuclear factor erythroid 2--related factor 2 (Nrf-2) by Ac ([@B25]) would contribute to its toxicity and of other active metabolites of CY such as phosphoramide mustard. There is also the possibility of GSH depletion in children with normal GSTM1 function when they receive BU especially in children older than 4 years of age ([@B3]), which might also increase the toxicity of Ac when CY is administered after BU as reported recently by our group in a multicenter study ([@B2]).

It is demonstrated that the rate of Ac appearance in urine is more crucial for HC development, rather than the cumulative exposures of Ac ([@B1]). Inter-individual variability in the rate of Ac appearance, could be partly explained by CYP2C9 function due to genetic variations. Blood Ac levels were reported to reach up to 10.2 μM = 600 ng/mL in patients receiving 60 mg/kg of CY ([@B27]). Urinary Ac levels can reach up to 406.8 nM = 23 ng/mL and concentrations vary depending upon the urine volume. Furthermore, the time required for peak urinary levels vary (from 1 to 12 h) among individuals ([@B34]). In our study all children received MESNA. However, patients with normal CYP2C9, GSTM1 activity and older than 10 years of age with viruria may need alternate prophylactic measures possibly because of the increased rate of Ac formation and its increased delivery to the bladder. We did not measure urinary levels of either Su or Ac to provide a conclusive evidence for this hypothesis. Higher urinary levels of Su and Ac were assumed if higher plasma levels were observed due to their water soluble nature. A recent population pharmacokinetic modeling with genetic covariates showed that *CYP2C9* genotypes partly explained the variability in CY pharmacokinetics ([@B6]). It is possible that an increased rate of Ac formation is due to the normal function of CYP2C9. However, a combined influence of various CYP isoforms in CY metabolism should not be ignored, especially those of CYP2B6 and CYP2C19. However, in this study we did not find an association of HC with the genetic variants analyzed in these two genes.

In addition to the genotypes, age was significantly associated with HC. In this cohort children older than 10 years of age had higher HC incidences. It is known that primary BK virus infection occurs at a younger age and at 10 years of age 50% of the population are seropositive ([@B18]; [@B33]). In our cohort 73% of the children with HC had BK viruria, and 9% had JC viruria at the time of HC diagnosis indicating a predominant role of viral infection in HC etiology, with contribution of other factors such as damage by CY metabolites, increased viral replication due to poor immune reconstitution, immunosuppression. However, we do not have viral infection data from the patients without HC to attribute its etiology unconditionally to viruria. Observations from this cohort indicate that in pediatric patients receiving BU-CY regimen prior to allogeneic HSCT age, viral infection status, *CYP2C9* and *GSTM1* genotype status are important predictors of HC occurrence. These risk factors could be added to the existing risk factors to develop a risk score for patient stratification for the implementation of effective prophylactic measures. However, this study is limited by its retrospective nature including patients recruited over a prolonged time period of more than 10 years. The changing practices over time and heterogeneity of the patient population included are the other limitations of this study. No differentiation of early or late onset of HC was considered in this study, in fact we investigated HC occurrence throughout the engraftment period which on average is defined as 30 days post HSCT owing to the two different sources, i.e., cord blood and bone marrow used in our cohort. This time frame allowed us to evaluate the genetic association with consideration of the degree of immunosuppression, viral impact, aGVHD influence, donor type, and immune reconstitution. The genetic association observed in this study should be interpreted in view of the following limitations: (a) the small sample size especially for Su level measurements, (b) dearth of data on the impact of Su on enzymes such as GSTs and ALDH. (c) Lack of data on the plasma or urinary Ac levels from these children. Overall, findings of this study strongly encourage further investigation into the impact of Su on the function of enzymes other than CYPs in the metabolic pathways of both BU and CY. Further investigations are also warranted to assess the relationship between (i) Su and Ac levels, (ii) *CYP2C9, GSTM1* genotype status, Ac levels and HC in a larger set of samples.

We did observe a trend of worse event-free survival (54.5 vs. 70.5%; *p* = 0.2) and OS (64 vs. 84%; *p* = 0.12) in patients who developed HC (data not shown). Irrespective of whether HC affects survival or not, it is associated with morbidity and long-term hospitalization which could be minimized with prior identification of high risk patients. In high risk patients CY may be replaced by fludarabine, thus reducing the risk of infections and toxicity with similar clinical outcomes provided the patient has a disease with lower risk of relapse and a matched related donor is available ([@B7]). Moreover, the preventive measures and treatment options for HC are not optimized, stratifying patients could aid in evaluating the choice of treatment and preventive measures prospectively, for example, prolonging hyperhydratation, use of prostaglandin derivatives, chemokine antagonists, use of bacterial or antiviral prophylaxis in high risk patients.

Conclusion
==========

High risk patients for HC can be identified based on the criteria of: older than 10 years of age, carrying normal *CYP2C9* and *GSTM1* genotypes, and having viral infections. This particular group shall be selected for evaluating different preventive measures to avoid morbidity and long term hospitalization due to HC. Ac is toxic to urothelial cells at concentrations of 33 μM. Su is not toxic to urothelial cells and does not affect the CYP function. Confirmation of this genetic association in an independent cohort is essential before it can be incorporated along with other known risk factors to develop a risk score for patient stratification in clinical care.
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